ARS Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own10.50% Shs Outstand95.43M Perf Week12.94%
Market Cap648.58M Forward P/E- EPS next Y-2.17 Insider Trans0.08% Shs Float62.98M Perf Month12.04%
Income-85.40M PEG- EPS next Q-0.32 Inst Own34.30% Short Float / Ratio1.30% / 4.60 Perf Quarter35.01%
Sales2.41M P/S269.23 EPS this Y-169.80% Inst Trans16.08% Short Interest0.82M Perf Half Y93.35%
Book/sh7.53 P/B0.93 EPS next Y-4.80% ROA-28.20% Target Price5.00 Perf Year-2.92%
Cash/sh2.87 P/C2.43 EPS next 5Y- ROE-29.60% 52W Range2.80 - 7.55 Perf YTD4.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.49% Beta-
Dividend %- Quick Ratio67.90 Sales past 5Y- Gross Margin- 52W Low149.29% ATR0.50
Employees92 Current Ratio67.90 Sales Q/Q-73.30% Oper. Margin- RSI (14)66.53 Volatility7.52% 9.50%
OptionableYes Debt/Eq0.00 EPS Q/Q22.20% Profit Margin- Rel Volume1.34 Prev Close6.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume177.56K Price6.98
Recom3.00 SMA2013.83% SMA5021.72% SMA20054.29% Volume237,513 Change7.72%
Nov-10-22 08:00AM
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scott Kathleen D.Chief Financial OfficerNov 29Buy6.248,25051,5068,250Dec 01 04:31 PM